Last reviewed · How we verify
Levocetirizine oral solution
Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.
Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria, Allergic conjunctivitis.
At a glance
| Generic name | Levocetirizine oral solution |
|---|---|
| Also known as | Xyzal |
| Sponsor | UCB Pharma |
| Drug class | H1-receptor antagonist (second-generation antihistamine) |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine that selectively antagonizes peripheral H1 receptors. By blocking histamine binding to H1 receptors on mast cells, basophils, and endothelial cells, it prevents the release and effects of histamine, thereby reducing allergic symptoms such as itching, urticaria, and rhinitis without significant central nervous system penetration.
Approved indications
- Allergic rhinitis (seasonal and perennial)
- Chronic urticaria
- Allergic conjunctivitis
Common side effects
- Somnolence
- Headache
- Fatigue
- Dry mouth
- Pharyngitis
Key clinical trials
- A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3) (PHASE3)
- Characterization of the Role of Histamine in Children With Asthma (PHASE2, PHASE3)
- Pharmacokinetic Study of Levocetirizine Oral Solution (PHASE1)
- Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics (PHASE3)
- Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levocetirizine oral solution CI brief — competitive landscape report
- Levocetirizine oral solution updates RSS · CI watch RSS
- UCB Pharma portfolio CI